Citius Pharmaceuticals Inc (CTXR) Stock Price, Quote & News

Company Profile

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic reli...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 967 6677

Website: citiuspharma.com

Address:

11 Commerce Drive, First Floor, Cranford, United States

NYC100 Feb. 23 at 4:41 PM

$CTOR $CTXR if it’s the way you say then, why are you mad? 😂😂

1 · Reply

SweStonk Feb. 23 at 3:45 PM

$CTXR $CTOR SixSevenSixSeven $0.6 was bound to happen just as I said, several times. These fake bulls know nothing about this company! We all know they got stuck from last pump and cant accept the loss for what it is. They probably gonna hold until next dilution and R/S until they STFU and move on.

0 · Reply

Bbboston Feb. 22 at 1:06 PM

$CTXR Hmm, Citius pharma develops nothing! Nada, zilch. Look it up!

0 · Reply

Applebat Feb. 18 at 12:57 PM

$CTXR https://youtube.com/clip/UgkxtNbSiSgKj5tlbA_ZVnhvAEX0-CGvqocJ?si=M82WJFq35TZVPZVS

1 · Reply

TwongStocks Feb. 17 at 7:56 PM

$CTXR 13G field by CVI Investments/Heights Capital management. https://www.sec.gov/Archives/edgar/data/1506251/000164955326000024/xslSCHEDULE_13G_X01/primary_doc.xml Beneficial ownership of 2,394,725 shares, 9.9% ownership. Per Item 4 of the filing, the beneficial ownership consists of 799,934 Shares & the rest in warrants. The shares/warrants are owned by CVI. Heights Capital is the investment manager of CVI. CVI/Heights Capital Management was the investor in CTXR's Oct offering (1,460,000 shares, 2,513,510 prefunded warrants, & 3,973,510 warrants). Due to the 9.99% ownership provision from that offering, CVI/Heights can only report a max beneficial ownership of 9.99%.

1 · Reply

CapitalProvenance Feb. 17 at 1:32 PM

$CTXR Pre-revenue biotech; early-stage.

1 · Reply

MAGApatriot Feb. 16 at 11:15 PM

$CTXR https://academic.oup.com/ofid/article/13/Supplement_1/ofaf695.330/8420393?utm_source=chatgpt.com&login=false Poster/abstract describing an international Phase 3 RCT in CLABSI/CRBSI patients with long-term central venous catheters, comparing Mino-Lok (minocycline/EDTA/ethanol antimicrobial lock) + systemic antibiotics vs site-specific standard-of-care lock + systemic antibiotics, with results framed around catheter salvage/retention and time-to-catheter failure. Disclosures (summary of personnel): - Several authors disclose research/grant support from $CTXR (Citius Pharmaceuticals) for study-related work including relationships with large pharmas (e.g., $PFE, $GILD) via grants/consulting.

0 · Reply

Boldtomilions Feb. 16 at 10:10 PM

$CTXR how do they spend $5.8M in three months on management pay and expect to have cash? Let me see if anyone will be dumb enough to borrow these jokers more money. This nonesense has to stop. They should be out of cash by May, and this nonesense stops. If they don’t have better sales numbers or some good progress on mini-lok for shareholders, they don’t deserve your money. Please don’t make the mistake I made investing in this useless management and company

0 · Reply

Boldtomilions Feb. 16 at 10:00 PM

$CTXR theee months ending dec 31st Sales $3.9M Gross profit $790K GENERAL AND ADMINISTRATIVE $5.7M😂😂😂 They are criminals. How do you spend $5.7M in three months on SGnA for a start up company that is deep in debt. Stay away from this company until these jokers proof that they deserve your hard earned money

1 · Reply

Marketman707 Feb. 16 at 1:23 PM

$CTXR management team: “What’s the plan after launch?” “ NO PLAN, GO ALL THE WAY, NO STOPS!”. Hmm…

0 · Reply

Market Cap	15.87M
Revenue (ttm)	0.00
Net Income (ttm)	-37.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	245,300
Avg Vol	883,188
Day's Range	N/A - N/A
Shares Out	22.38M
Stochastic %K	14%
Beta	1.61
Analysts	Sell
Price Target	$6.00